
Garrick C Stewart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6731142/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Myocarditis in the Setting of Cancer Therapeutics. Circulation, 2019, 140, 80-91.	1.6	278
2	Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. Journal of Nuclear Cardiology, 2014, 21, 166-174.	2.1	242
3	Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2018, 11, e007030.	2.6	187
4	Mechanical Circulatory Support for Advanced Heart Failure. Circulation, 2012, 125, 1304-1315.	1.6	182
5	Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. Journal of Nuclear Cardiology, 2018, 25, 1136-1146.	2.1	121
6	Patient Expectations From Implantable Defibrillators to Prevent Death in Heart Failure. Journal of Cardiac Failure, 2010, 16, 106-113.	1.7	110
7	Advanced Heart Failure. Heart Failure Clinics, 2016, 12, 323-333.	2.1	91
8	Randomized, Controlled Trial of an Advance Care Planning Video Decision Support Tool for Patients With Advanced Heart Failure. Circulation, 2016, 134, 52-60.	1.6	84
9	The Many Faces of Heart Failure. Cardiac Electrophysiology Clinics, 2019, 11, 11-20.	1.7	80
10	Implant Strategies Change Over Time and Impact Outcomes. JACC: Heart Failure, 2013, 1, 369-378.	4.1	72
11	Myocardial Parvovirus B19 Persistence. Circulation: Heart Failure, 2011, 4, 71-78.	3.9	60
12	INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	59
13	Keeping Left Ventricular Assist Device Acceleration on Track. Circulation, 2011, 123, 1559-1568.	1.6	58
14	Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2019, 12, e008975.	2.6	54
15	Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. Journal of Heart and Lung Transplantation, 2019, 38, 408-417.	0.6	47
16	Thresholds of Physical Activity and Life Expectancy for Patients Considering Destination Ventricular Assist Devices. Journal of Heart and Lung Transplantation, 2009, 28, 863-869.	0.6	40
17	INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry. Journal of Heart and Lung Transplantation, 2020, 39, 16-26.	0.6	38
18	Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure, IACC: Heart Failure, 2017, 5, 663-671.	4.1	33

GARRICK C STEWART

#	Article	IF	CITATIONS
19	High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry. Journal of Heart and Lung Transplantation, 2016, 35, 722-730.	0.6	28
20	Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced HeartÂFailure. JACC: Heart Failure, 2021, 9, 226-236.	4.1	26
21	Heart Transplantation in Adults with Congenital Heart Disease. Heart Failure Clinics, 2014, 10, 207-218.	2.1	23
22	A History of Devices as an Alternative to Heart Transplantation. Heart Failure Clinics, 2014, 10, S1-S12.	2.1	21
23	Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot. Journal of Heart and Lung Transplantation, 2015, 34, 1630-1633.	0.6	21
24	Cardiac Sarcoidosis: When and How to Treat Inflammation. Cardiac Failure Review, 2021, 7, e17.	3.0	18
25	Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. Journal of Thrombosis and Thrombolysis, 2018, 46, 180-185.	2.1	16
26	Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. Journal of Heart and Lung Transplantation, 2020, 39, 27-36.	0.6	15
27	INTERMACS and MedaMACS: How Will They Guide Future Therapy?. Current Cardiology Reports, 2013, 15, 394.	2.9	14
28	Ambulatory Advanced Heart Failure inÂWomen. JACC: Heart Failure, 2019, 7, 602-611.	4.1	14
29	Registry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL): Rationale, design, baseline characteristics, and inclusion criteria performance. Journal of Heart and Lung Transplantation, 2020, 39, 7-15.	0.6	13
30	Evaluation of Bend Relief Disconnection in Patients Supported by a HeartMate II Left Ventricular Assist Device. Circulation: Cardiovascular Imaging, 2014, 7, 844-848.	2.6	12
31	The Risk of Stroke on Left Ventricular Assist Device Support. JACC: Heart Failure, 2017, 5, 712-714.	4.1	12
32	Impact of Socioeconomic Factors on Patient Desire for Early LVAD Therapy Prior to Inotrope Dependence. Journal of Cardiac Failure, 2020, 26, 316-323.	1.7	9
33	ldentifying Stage D Heart Failure: Data From the Most Recent Registries. Current Heart Failure Reports, 2019, 16, 130-139.	3.3	7
34	Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients. Circulation: Heart Failure, 2020, 13, e006858.	3.9	7
35	Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond. Current Heart Failure Reports, 2017, 14, 498-506.	3.3	6
36	Caregiver Healthâ€Related Quality of Life, Burden, and Patient Outcomes in Ambulatory Advanced Heart Failure: A Report From REVIVAL. Journal of the American Heart Association, 2021, 10, e019901.	3.7	6

GARRICK C STEWART

#	Article	IF	CITATIONS
37	Multimodality Imaging of Hypertrophic Cardiomyopathy in a Transplanted Heart. Circulation, 2014, 130, 1010-1013.	1.6	5
38	Left ventricular dimension decrement index early after axial flow assist device implantation: A novel risk marker for late pump thrombosis. Journal of Heart and Lung Transplantation, 2015, 34, 1561-1569.	0.6	5
39	Finding the Right Time and Place to Vent. JACC: Heart Failure, 2018, 6, 1044-1046.	4.1	5
40	Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry. Journal of Cardiac Failure, 2022, 28, 765-774.	1.7	5
41	Management of Peripartum Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 622-636.	0.9	4
42	Patients report more severe daily limitations than recognized by their physicians. Clinical Cardiology, 2019, 42, 1181-1188.	1.8	4
43	Clinical characteristics and outcomes of patients requiring prolonged inotropes after left ventricular assist device implantation. Artificial Organs, 2020, 44, E382-E393.	1.9	4
44	An early relook identifies high-risk trajectories in ambulatory advanced heart failure. Journal of Heart and Lung Transplantation, 2022, 41, 104-112.	0.6	4
45	Learning From Our Predictions. JACC: Heart Failure, 2016, 4, 959-961.	4.1	2
46	Postoperative bridging anticoagulation and left ventricular assist system thrombosis. Journal of Thrombosis and Thrombolysis, 2019, 47, 57-66.	2.1	2
47	Giant Left Atrium. New England Journal of Medicine, 2008, 358, 2050-2050.	27.0	1
48	Mapping the Terrain of Competing Risk Following Primary Prevention Defibrillator Implantation. Circulation: Heart Failure, 2015, 8, 847-849.	3.9	1
49	Finding Traction for Mechanical Circulatory Support During Coronary Interventions. Circulation, 2015, 132, 1221-1223.	1.6	0
50	Putting Life in the Years. Circulation: Heart Failure, 2016, 9, .	3.9	0
51	A 52-Year-Old Man With Unheralded Syncope. JAMA Cardiology, 2017, 2, 1394.	6.1	0
52	Editorial commentary: Weaving palliative care into the fabric of heart failure management. Trends in Cardiovascular Medicine, 2018, 28, 451-452.	4.9	0
53	Body Fat and Fitness for Ventricular Assist Device Therapy. Journal of Cardiac Failure, 2020, 26, 298-299.	1.7	0